Prevention of GVHD is one of the most desirable goals of BMT in aplastic anemia (AA). We reviewed the medical records of 24 consecutive patients treated with BMT for acquired AA using two different GVHD prevention strategies. Ten patients were given alemtuzumab-based GVHD prophylaxis (50-60 mg in three divided doses on days À8, À7 and À6), and 14 patients were given conventional GVHD prophylaxis with calcineurin inhibitors plus MTX before the introduction of the alemtuzumab-based protocols. The incidence of acute, chronic and 'serious GVHD' was significantly reduced in alemtuzumab-treated patients compared to conventionally treated patients [11 vs 64% (P ¼ 0.03), 0 vs 78% (P ¼ 0.002) and 0 vs 57% (P ¼ 0.007), respectively]. Engraftment time and rates of graft failure appeared similar in the two groups. A significantly higher proportion of alemtuzumab-treated patients developed CMV reactivation compared to control patients (83 vs 12%; P ¼ 0.03); none developed CMV disease. The rates of other infectious complications did not appear significantly different. Our data suggest that 50-60 mg of alemtuzumab given according to the current schedule significantly reduces the risk of GVHD without increasing the risk of graft failure or serious infections.
Introduction
The goal of BMT in acquired aplastic anemia (AA) is sustained engraftment with minimal regimen-related toxicities and GVHD. Randomized studies in patients with AA have shown that the combination of CsA and MTX is superior to either agent alone for prevention of GVHD. [1] [2] [3] At present, CsA and MTX is the most commonly used GVHD prophylaxis regimen for AA. In addition to CsA and MTX, some centers use antithymocyte globulin (ATG) in conditioning protocols for AA. 4, 5 Despite these strategies, 30-40% of patients develop acute and chronic GVHD, which not only result in morbidity and mortality but also have a negative impact on the quality of life. [4] [5] [6] [7] Unlike hematologic malignancies, GVHD probably has no therapeutic benefit in patients with AA and prevention of GVHD is one of the most desirable goals of BMT in AA. Previous studies from St George's Hospital in London reported a favorable effect on acute and chronic GVHD in matched sibling donor and matched unrelated donor BMT for AA using in vivo anti-CD52 monoclonal antibodies (Campath-1G antibodies and alemtuzumab). 8, 9 The main concerns with the use of anti-CD52 antibodies include a high risk of graft failure 8 and increased risk of infectious complications. [10] [11] [12] Previous observations in patients with AA also showed that the risk of graft failure was higher when in vivo anti-CD52 antibodies were administered both before and after stem cell infusion. 8 Graft rejection was reduced when anti-CD52 antibodies were administered only before stem cell infusion, indicating that the timing of anti-CD52 antibodies may be an important factor. 8 In addition to different dosing schedules, previous studies used a high dose of anti-CD52 antibodies (75-100 mg). 8, 9, 13 Reducing the dose of anti-CD52 antibodies may decrease the incidence of infectious complications. Recently, a study from Sweden in patients with hematological malignancies suggested that a lower dose of alemtuzumab (30 mg) results in a lower risk of infectious complications and faster immune reconstitution. 14 To optimize the use of alemtuzumab in BMT for AA, we used a relatively lower dose of alemtuzumab (50-60 mg) divided into three doses given on days À8, À7 and À6 at Princess Margaret Hospital, Toronto. In this observational study, we analyze the outcomes of 10 consecutive patients treated with alemtuzumab-based GVHD prophylaxis and 14 consecutive patients who received calcineurin inhibitor plus MTX-based GVHD prophylaxis before implementation of alemtuzumab-based GVHD prophylaxis at our institution. The main outcomes of interest were engraftment, regimen-related toxicities, acute, chronic and 'serious GVHD', infectious complications and causes of death.
Patients and methods

Patients
This study includes 24 consecutive patients who underwent BMT for acquired AA at Princess Margaret Hospital (University Health Network, Toronto, Ontario, Canada). Ten patients were treated with alemtuzumab-based institutional protocols (MP-0404 and MP-0405) from September 2004 to December 2006. To understand the clinical problems associated with conventional GVHD prophylaxis, we also analyzed the outcomes of 14 consecutive patients from January 2000 to August 2004 treated before the introduction of the alemtuzumab-based protocols. The diagnosis of AA was established according to the criteria of the International Agranulocytosis and Aplastic Anemia Study. 15 The study was approved by the Research Ethics Board of the University Health Network.
Conditioning regimen and GVHD prophylaxis Alemtuzumab-treated patients. A risk-adapted strategy was used for the selection of conditioning chemotherapy. Patients under the age of 40 years with matched sibling donors were treated with high-dose CY (50 mg/kg i.v. once daily, days À5 to À2) with MESNA (12.5 mg/kg i.v. 4 times daily, days À5 to À2). Patients above the age of 40 years, below the age of 40 years with significant comorbidities or those receiving BMT from an unrelated donor were treated with a minimal intensity protocol consisting of fludarabine (30 mg/m 2 i.v. once daily, days À5 to À2) and low-dose CY (10 mg/kg i.v. once daily, days À5 to À2). CY was replaced with BU (3.2 mg/kg i.v. twice daily, days À5 to À2) in two patients. One of these two patients had monosomy 7 with BM biopsy findings consistent with AA. The other patient with severe aplastic anemia had a significant paroxysmal nocturnal hemoglobinuria clone resulting in hepatic vein thrombosis and was heavily transfused and refractory to platelet transfusions (190 transfusions). This patient was also given 200 cGy TBI.
Patients receiving high-dose CY were given 50 mg of alemtuzumab i.v. in divided doses of 10, 20 and 20 mg on days À8, À7 and À6, respectively. Patients receiving fludarabine-based conditioning were given 60 mg of alemtuzumab i.v. in divided doses of 10, 20 and 30 mg on days À8, À7 and À6, respectively. Premedication with diphenhydramine hydrochloride (50 mg p.o.; orally) and acetaminophen (650 mg p.o.) was given before alemtuzumab administration. CsA was started on day À1 pre transplant and was continued up to 6 months post transplant at which point tapering began unless there was an evidence of mixed chimerism, in which case it was continued longer. CsA was replaced with tacrolimus in two patients because of contraindications. One patient received mycophenolate mofetil due to end-stage renal disease as described previously. 16 CsA and tacrolimus doses were titrated to maintain trough levels between 200-400 ng/ml and 10-20 mg/l, respectively.
Control patients. All patients received high-dose CY (50 mg/kg i.v. once daily, days À5 to À2) with MESNA (12.5 mg/kg i.v. four times daily, days À5 to À2). Eight patients with a matched family donor received 300 cGy TBI in a single fraction on day 0. Two patients received 1200 cGy TBI (in six fractions), one had matched unrelated donor and the other had a large paroxysmal nocturnal hemoglobinuria clone. All patients received CsA as described above and a short course of MTX (15 mg/m 2 i.v. on day þ 1, 10 mg/m 2 i.v. on days þ 3, þ 6 and þ 11). Tacrolimus was substituted for CsA in one patient with contraindications. CsA and tacrolimus trough levels were maintained as described above. Five patients also received thymoglobulin (rabbit ATG; 2.5 mg/kg i.v. once daily, days À3 to À1).
Definitions and evaluation of response
Patients who received 450 platelet and/or RBC transfusions before BMT were considered heavily transfused. Platelet refractoriness was defined as a platelet increment of less than 10 Â 10 9 /l to random donor platelets 1 h after infusion of platelets in the absence of fever or bleeding.
Engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count 40.5 Â 10 9 /l. Patients were evaluable for engraftment, if they survived at least 21 days post transplant. Primary graft failure occurred when patients did not achieve absolute neutrophil count 40.5 Â 10 9 /l within 42 days post transplant. Patients who achieved initial engraftment, but subsequently developed severely hypocellular marrow or absolute neutrophil count o0.5 Â 10 9 /l were defined as having secondary graft failure. Platelet engraftment was defined as the first of 7 consecutive days with an unsupported platelet count 420 Â 10 9 /l. Regimen-related toxicities were evaluated from the start of conditioning therapy until 6 weeks post transplant according to the Bearman Criteria. 17 Patients who survived more than 14 and 100 days were evaluable for the occurrence of acute and chronic GVHD, respectively. Acute and chronic GVHD were scored according to previously described criteria. 18, 19 Serious GVHD was defined according to criteria described by Flowers et al. 20 and was considered present if it resulted in (1) death, (2) disability, (3) three or more major infections in 1 year, (4) prolonged hospitalization and (5) suicide or hospitalization for suicidal ideation.
Supportive care
Supportive care was provided as described previously. 21 In both alemtuzumab-treated and control patients, monitoring for CMV was performed in at-risk patients (CMV seropositive recipient or donor) by pp65 antigenemia testing on a weekly basis for the first 100 days and subsequently on clinic visits up to 1 year or according to clinical needs. Preemptive therapy with ganciclovir (5 mg/kg i.v. twice daily), delivered by ambulatory infusion pump, was started at antigen levels X2/100 000 cells and was continued for a minimum of 2 weeks, or until two consecutive negative samples taken 1 week apart. In addition to these measures, alemtuzumab-treated patients were given antifungal prophylaxis with itraconazole suspension (200 mg p.o. twice daily for 3 months) and acyclovir (200 mg p.o. twice daily for 3 months).
Chimerism studies
For patients treated with alemtuzumab, chimerism studies were performed on whole blood samples as described previously. 22 Testing was carried out at days 30, 60 and 120 post transplant, or according to clinical needs.
Absolute lymphocyte counts
Automated absolute lymphocyte counts (ALCs) were obtained in all patients at baseline and at 1, 3, 6, 9 and 12 months post transplant.
Statistical analysis
Results were considered significant, if the two-sided P-value was p0.05. The statistical analysis was performed using Version 9.1 of the SAS system and user's Guide (SAS Institute, Cary, NC, USA).
Results
Baseline patient-, disease-and transplant-related characteristics are shown in Table 1 . Of particular note, a significantly higher proportion of alemtuzumab-treated patients were heavily transfused before BMT and received fludarabine-based conditioning compared to control patients.
Alemtuzumab was well tolerated. The majority of patients (90%) had infusion-related side effects with the first dose, but none required discontinuation of alemtuzumab. In the control group, of five patients who received ATG as part of the conditioning regimen, one required discontinuation due to severe systemic side effects.
The outcomes of study patients are summarized in Table 2 . A significantly larger number of control patients experienced regimen-related toxicities (Bearman Xgrade II) in the form of stomatitis, and hepatic and renal toxicity compared to the alemtuzumab-treated patients ( Table 2) .
No significant difference was noted in rates of graft failure or time to platelet and neutrophil enraftment between the alemtuzumab and control groups. Chimerism evaluations in alemtuzumab-treated patients at days 30, 60 and 120 post transplant showed median donor chimerism of 97% (range: 86-99), 98% (range: 88-100) and 98% (range: 94-100), respectively. One patient had mixed donor chimerism of 73% at the last evaluation (13 months post transplant), but remains transfusion independent. The control group had significantly higher rates of acute (grades II-IV), chronic (extensive) and serious GVHD in comparison to alemtuzumab-treated patients (Table 2) .
A significantly greater proportion of patients at risk for CMV reactivation in the alemtuzumab group experienced early (0-100 days post transplant) and late (101-365 days post transplant) CMV reactivation compared to similar control patients (Table 2) . No patients developed CMV disease. In the alemtuzumab group, the median time to CMV reactivation was 35 days (range: 32-40). Recurrent episodes of CMV reactivation were seen in patients treated with alemtuzumab with a median of three episodes (range: 2-5). The incidence of other infections appears similar between alemtuzumab-treated and control patients ( Table 2) .
A comparison of lymphocyte recovery in alemtuzumabtreated and control patients is shown in Figure 1 . Median ALCs at 1 month post transplant were significantly lower in alemtuzumab-treated patients at 0.10 Â Median follow-up of survivors in the alemtuzumab and control groups were 23 months (range: 13-30) and 52 months (range: 39-84), respectively. Two patients in the GVHD prevention in AA D Siegal et al control group underwent second BMT due to graft failure. At last follow-up, all survivors were transfusion independent.
Discussion
Our data show that using an alemtuzumab-based GVHD prevention strategy, the risk of GVHD can be significantly reduced. The incidence of acute, chronic and serious GVHD was significantly decreased in patients treated with alemtuzumab compared to those treated with conventional GVHD prophylaxis ( Table 2 ). The incidence of acute and chronic GVHD in the control population appears high compared to that described in the literature. 4, 5, 23 This may be related to differences in the patient populations as the majority of previous studies included both pediatric and adult patients. Our study was confined only to adult patients. It can be debated that in the alemtuzumab group, the beneficial effect on GVHD may be contributed by other factors as a significant proportion of these patients received fludarabine-based conditioning and these two study cohorts may not be comparable. Our purpose of studying the control group was to understand the clinical issues in patients with AA undergoing BMT at our center and design the effective strategies so as to overcome these issues. The problem of GVHD in AA does not appear to be overcome by using fludarabine-based protocols alone. In a recent study, the incidence of acute and chronic GVHD was 29 and 32%, respectively in patients with AA treated with fludarabine-and CY-based conditioning using CsA-and MTX-based GVHD prophylaxis. 24 A concern has been raised regarding a higher incidence of graft failure using anti-CD52 antibodies. However, the graft failure may be related to the schedule of anti-CD52 antibody administration. In our study, there did not appear to be a difference between alemtuzumab-treated and control patients with regard to engraftment or graft failure. This confirms the results from a previous study in which a lower incidence of graft failure was seen in patients receiving anti-CD52 antibodies before stem cell infusion, and suggests that the timing of alemtuzumab is important in reducing the risk of graft failure. 8 Chimerism studies showed that all except one patient in the alemtuzumab group had sustained donor engraftment.
The alemtuzumab cohort experienced less regimenrelated toxicities than the control group, specifically with respect to stomatitis and hepatic and renal toxicity ( Table 2) . A lower incidence of regimen-related toxicities may be related to a risk-adapted strategy for the choice of conditioning regimen, as a significant number of alemtuzumab-treated patients were conditioned with a fludarabine-based minimal intensity regimen. In addition, alemtuzumab-treated patients received CsA alone without MTX for GVHD prophylaxis. MTX-containing GVHD prophylaxis are known to be associated with a higher incidence of stomatitis. 25 Apart from CMV reactivation, there did not appear to be a difference in overall rates of infectious complications between the alemtuzumab and control groups. Alemtuzumab-treated patients experienced significantly more episodes of early and late CMV reactivation than control patients ( Table 2) . One of the alemtuzumab-treated patients died of EBV-associated lymphoproliferative disorder. Preliminary results of a recent study from St George's Hospital in London analyzed 89 transplant patients with AA and found an incidence of 5% of EBVrelated lymphoproliferative disorder in this patient population. 26 There was no apparent difference between ATG and alemtuzumab treated-patients. However, it appears that the incidence was greater in patients who failed ATG-based immunosuppression before BMT. From these data, it appears that close monitoring for EBV should be carried out in the post transplant period especially in patients who had failed immunosuppression before BMT.
Analysis of lymphocyte count recovery showed significantly low ALCs at 1 month post transplant in the alemtuzumab group in comparison to the control group. No significant differences were found at 3, 6, 9 and 12 months post transplant. This observation has to be interpreted cautiously due to the small sample size. However, it seems reasonable to continue antifungal and antiviral prophylaxis up to 3 months post transplant in alemtuzumab-treated patients.
The main limitation of our study is the small number of patients. The rarity of AA is a major barrier in conducting large prospective studies. Overall, these data suggest that GVHD can be significantly reduced without increasing the risk of graft failure or serious infections using 50-60 mg of alemtuzumab according to the current schedule. At our center, we have further reduced the dose of alemtuzumab to 30 mg in patients with hematological malignancies. With this approach, approximately 40% of patients develop GVHD (unpublished data, V Gupta). Therefore, for disorders such as AA or other non-malignant disorders where a GVL effect is not required, it may be reasonable to investigate 50-60 mg of alemtuzumab in future studies. 
